Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
NCT03379428Phase 2Active, not recruiting
- Sponsor
- US Oncology Network
- Start
- Nov 2017
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in breast cancer, sponsored by US Oncology Network. Started Nov 2017; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03379428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03379428.